Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease.
- Author:
Qing-Fei HAO
1
;
Guang-Yao SHENG
;
Zuo LUAN
Author Information
1. Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. haoqingfei@hotmail.com.
- Publication Type:Journal Article
- MeSH:
Epstein-Barr Virus Infections;
complications;
therapy;
Hematopoietic Stem Cell Transplantation;
adverse effects;
Humans;
Immunotherapy;
methods;
Lymphoproliferative Disorders;
etiology;
therapy;
Postoperative Complications;
etiology;
therapy;
Risk Factors
- From:
Chinese Journal of Contemporary Pediatrics
2013;15(9):795-799
- CountryChina
- Language:Chinese
-
Abstract:
Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disease (EBV-PTLD) is a potentially life-threatening complication after hematopoietic stem cell transplantation or solid organ transplantation. In the last decade, the survival of patients with EBV-PTLD has been significantly improved by immunotherapeutic interventions among high-risk patients. The immunotherapeutic interventions for EBV-PTLD include reduction in immunosuppression, CD20 monoclonal antibodies (rituximab) as monotherapy or in combination with chemotherapy, and adoptive immunotherapy with EBV-specific T cells. This paper reviews the latest update on the high-risk factors, clinical manifestations and immunotherapy of EBV-PTLD.
